A005690 Stock Overview
A biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Pharmicell Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩5,630.00 |
52 Week High | ₩8,490.00 |
52 Week Low | ₩5,290.00 |
Beta | 0 |
1 Month Change | 2.18% |
3 Month Change | -16.34% |
1 Year Change | -25.53% |
3 Year Change | -68.01% |
5 Year Change | -32.57% |
Change since IPO | 132.82% |
Recent News & Updates
Recent updates
Shareholder Returns
A005690 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -1.1% | -4.8% | 1.7% |
1Y | -25.5% | 13.3% | 4.5% |
Return vs Industry: A005690 underperformed the KR Biotechs industry which returned 13.3% over the past year.
Return vs Market: A005690 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
A005690 volatility | |
---|---|
A005690 Average Weekly Movement | 4.5% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.2% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A005690 has not had significant price volatility in the past 3 months.
Volatility Over Time: A005690's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1968 | n/a | Hyun-Soo Kim | www.pharmicell.com |
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.
Pharmicell Co., Ltd. Fundamentals Summary
A005690 fundamental statistics | |
---|---|
Market cap | ₩337.82b |
Earnings (TTM) | -₩26.78b |
Revenue (TTM) | ₩23.94b |
0.0x
P/S Ratio0.0x
P/E RatioIs A005690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A005690 income statement (TTM) | |
---|---|
Revenue | ₩23.94b |
Cost of Revenue | ₩18.50b |
Gross Profit | ₩5.45b |
Other Expenses | ₩32.23b |
Earnings | -₩26.78b |
Last Reported Earnings
Jun 30, 2014
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A005690 perform over the long term?
See historical performance and comparison